Back to List View Graph View

Denosumab

Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor κ-B ligand (RANKL), a key Signaling molecule in osteoclast differentiation, activation, and survival.

Where the papers sit

10 papers from the last 6 months study denosumab directly · updated from PubMed 13 Nov 2026

Those 10 are all about one subject.

  • Clinical Osteoporosis Management

    Osteoporosis management is moving toward longer-term, individualized antiresorptive care. Discontinuation patterns, adherence interventions, bone mineral density, and fracture risk recur as practical endpoints, while sequential romosozumab–denosumab therapy is being assessed for severe disease. Long-term safety remains central, including medication-related osteonecrosis of the jaw and cardiovascular outcomes with romosozumab. The literature also flags denosumab interference in serum protein electrophoresis and exploratory use with pembrolizumab in renal-cell carcinoma.

    10 papers

NEW DIRECTION

Denosumab is also a diagnostic interferent in monoclonal-protein testing

The serum protein electrophoresis study of denosumab found that, beyond its therapeutic use, the antibody migrates in the gamma region and can complicate interpretation of serum protein electrophoresis and immunofixation in patients with multiple myeloma; mass spectrometry can distinguish it from endogenous M-proteins, adding denosumab recognition to monoclonal-protein assessment 42847316Oct.

NEW DIRECTION

Denosumab is being developed as an immunotherapy-potentiating partner rather than solely as bone-directed treatment

The phase 2 study of pembrolizumab plus denosumab in pretreated advanced clear-cell renal-cell carcinoma assigned denosumab a role as an adjunct intended to inhibit RANKL signaling and potentially enhance immune-checkpoint inhibition, extending its use from bone disease management to combination anticancer immunotherapy 42336709Jun.

Papers

The 10 papers from the last 6 months that study denosumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Clinical Osteoporosis Management (10)
  1. Real-world treatment patterns following denosumab discontinuation: a descriptive epidemiological study. Archives of osteoporosis · 12 Nov 2026 PMID 43018839
  2. Baseline characteristics and bone mineral density changes associated with lower fracture risk in osteoporosis: a retrospective cohort study. Rheumatology international · 16 Oct 2026 PMID 42888324
  3. Investigating Denosumab Interference in Serum Protein Electrophoresis. The journal of applied laboratory medicine · 8 Oct 2026 PMID 42847316
  4. Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab-Denosumab Therapy for Severe Osteoporosis. Yonsei medical journal · 24 Aug 2026 PMID 42634293
  5. Long-term effects of denosumab: a 10-year single-center retrospective study. Archives of osteoporosis · 19 Aug 2026 PMID 42616205
  6. Revisiting the activate depress free and repeat (ADFR) paradigm: Clinical use of cyclic romosozumab. Archives of osteoporosis · 14 Aug 2026 PMID 42599329
  7. Impact of clinical pharmacist-led interventions on denosumab adherence. Archives of osteoporosis · 6 Aug 2026 PMID 42560392
  8. Osteoporosis medication exposure patterns and MRONJ occurrence in patients receiving romosozumab: a retrospective observational study. Clinical oral investigations · 12 Jul 2026 PMID 42437851
  9. Cardiovascular Safety of Romosozumab Versus Other Anti-Osteoporosis Medications in Patients with Osteoporosis: A Nationwide Health Insurance Claims Database Study in Japan. Calcified tissue international · 9 Jul 2026 PMID 42423749
  10. Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma. Clinical genitourinary cancer · 23 Jun 2026 PMID 42336709

By study type

Clinical trials (1)
  1. Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma. Clinical genitourinary cancer · 23 Jun 2026 PMID 42336709
Observational studies and case reports (6)
  1. Baseline characteristics and bone mineral density changes associated with lower fracture risk in osteoporosis: a retrospective cohort study. Rheumatology international · 16 Oct 2026 PMID 42888324
  2. Investigating Denosumab Interference in Serum Protein Electrophoresis. The journal of applied laboratory medicine · 8 Oct 2026 PMID 42847316
  3. Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab-Denosumab Therapy for Severe Osteoporosis. Yonsei medical journal · 24 Aug 2026 PMID 42634293
  4. Long-term effects of denosumab: a 10-year single-center retrospective study. Archives of osteoporosis · 19 Aug 2026 PMID 42616205
  5. Revisiting the activate depress free and repeat (ADFR) paradigm: Clinical use of cyclic romosozumab. Archives of osteoporosis · 14 Aug 2026 PMID 42599329
  6. Osteoporosis medication exposure patterns and MRONJ occurrence in patients receiving romosozumab: a retrospective observational study. Clinical oral investigations · 12 Jul 2026 PMID 42437851
Human data, design not indexed (3)
  1. Real-world treatment patterns following denosumab discontinuation: a descriptive epidemiological study. Archives of osteoporosis · 12 Nov 2026 PMID 43018839
  2. Impact of clinical pharmacist-led interventions on denosumab adherence. Archives of osteoporosis · 6 Aug 2026 PMID 42560392
  3. Cardiovascular Safety of Romosozumab Versus Other Anti-Osteoporosis Medications in Patients with Osteoporosis: A Nationwide Health Insurance Claims Database Study in Japan. Calcified tissue international · 9 Jul 2026 PMID 42423749